Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.94 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.85 |
| ▸ | CDK4 | P11802 | 1/20 | 0.85 |
| ▸ | CCND1 | P24385 | 1/20 | 0.85 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.85 |
| ▸ | CDK2 | P24941 | 1/20 | 0.85 |
| ▸ | PRKCA | P17252 | 3/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30319849 | 0.92 | CCNE2 (1.00) | GSK3BCCNE2CDK4CCND1CCNE1 | |
| SCHEMBL5686048 | 0.92 | CCNE2 (1.00) | GSK3BCCNE2CDK4CCND1CCNE1 | |
| SCHEMBL8167092 | 0.89 | CDK2 (0.76) | GSK3BCCNE2CDK4CCND1CCNE1 | |
| SCHEMBL8153807 | 0.89 | GSK3B (0.81) | GSK3BCCNE2CDK4CCND1CCNE1 | |
| SCHEMBL8166880 | 0.89 | GSK3B (0.81) | GSK3BCCNE2CDK4CCND1CCNE1 | |
| SCHEMBL8154477 | 0.87 | GSK3B (0.77) | GSK3BCCNE2CDK4CCND1CCNE1 | |
| SCHEMBL8154180 | 0.87 | GSK3B (0.76) | GSK3BCCNE2CDK4CCND1CCNE1 | |
| SCHEMBL8161378 | 0.87 | GSK3B (0.77) | GSK3BCCNE2CDK4CCND1CCNE1 | |
| SCHEMBL8162888 | 0.86 | CCNE2 (0.76) | GSK3BCCNE2CDK4CCND1CCNE1 | |
| SCHEMBL4427029 | 0.86 | GSK3B (1.00) | GSK3BCCNE2CDK4CCND1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030087949-A1 | Indolylpyrrole derivatives and cell death inhibitors | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2003-05-08 | — | — | US | disclosed |
| EP-1275646-A1 | INDOLYLPYRROLE DERIVATIVES AND CELL DEATH INHIBITORS | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2003-01-15 | — | — | EP | disclosed |
| US-RE36736-E | Substituted pyrroles | HOFFMAN-LA ROCHE INC. (US) | 2000-06-13 | — | — | US | disclosed |
| EP-0540956-B1 | Process for the manufacture of substituted maleimides | HOFFMANN LA ROCHE (CH) | 1997-09-03 | — | — | EP | disclosed |
| US-5399712-A | Protein kinase C inhibitor | HOFFMANN-LA ROCHE INC. (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0540956-A1 | Process for the manufacture of substituted maleimides | F. HOFFMANN-LA ROCHE AG (CH) | 1993-05-12 | — | — | EP | disclosed |
| EP-0328026-B1 | SUBSTITUTED PYRROLES | F. HOFFMANN-LA ROCHE AG (CH) | 1993-04-28 | — | — | EP | disclosed |
| US-5057614-A | Antiinflammatory, immunology, bronchodilator agents, cardiovascular disorders | HOFFMANN-LA ROCHE INC. (US) | 1991-10-15 | — | — | US | disclosed |
| EP-0328026-A1 | Substituted pyrroles | F. HOFFMANN-LA ROCHE AG (CH) | 1989-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087949-A1 | Indolylpyrrole derivatives and cell death inhibitors | AIFM1, BAX, CASP3 | GSK3B 181/4885CCNE2 1210/4885CDK4 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.